Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants with HPP
Study Identifier:
D8590C00003
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
Recruiting
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: ALXN1850
- Drug: Placebo
Date
May 2024 - Dec 2025
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 2 - 11 Years
Requirements Information
Sex
Female & Male
Age
2 - 11 Years
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: ALXN1850
- Drug: Placebo
Date
May 2024 - Dec 2025
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 2 - 11 Years years
Requirements Information
Protocol Summary
The primary purpose of this study is to evaluate the efficacy of ALXN1850 versus
placebo on radiographic outcomes in pediatric participants with HPP who have not previously been treated with asfotase alfa.
Trial Locations
Location
Status
Location
Research Site
São Paulo, Unmapped, 01409-902
Status
Recruiting
Location
Research Site
Parkville, Unmapped, 3052
Status
Recruiting
Location
Research Site
Edmonton, Alberta, Canada, T6G 2H7
Status
Withdrawn
Location
Research Site
Ottawa, ON, Canada, K1H 8L1
Status
Recruiting
Location
Research Site
Manchester, United Kingdom
Status
Suspended
Location
Research Site
Ratchathewi, Unmapped, 10400
Status
Withdrawn